Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.92
PFE's Cash to Debt is ranked higher than
59% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. PFE: 0.92 )
PFE' s 10-Year Cash to Debt Range
Min: 0.14   Max: 3.47
Current: 0.92

0.14
3.47
Equity to Asset 0.45
PFE's Equity to Asset is ranked higher than
54% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. PFE: 0.45 )
PFE' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.66
Current: 0.45

0.37
0.66
Interest Coverage 11.11
PFE's Interest Coverage is ranked higher than
55% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. PFE: 11.11 )
PFE' s 10-Year Interest Coverage Range
Min: 5.27   Max: 46.18
Current: 11.11

5.27
46.18
F-Score: 6
Z-Score: 2.55
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 30.47
PFE's Operating margin (%) is ranked higher than
96% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. PFE: 30.47 )
PFE' s 10-Year Operating margin (%) Range
Min: 9.51   Max: 35.89
Current: 30.47

9.51
35.89
Net-margin (%) 42.65
PFE's Net-margin (%) is ranked higher than
98% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. PFE: 42.65 )
PFE' s 10-Year Net-margin (%) Range
Min: 8.74   Max: 42.65
Current: 42.65

8.74
42.65
ROE (%) 28.83
PFE's ROE (%) is ranked higher than
98% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. PFE: 28.83 )
PFE' s 10-Year ROE (%) Range
Min: 5.98   Max: 52.59
Current: 28.83

5.98
52.59
ROA (%) 12.78
PFE's ROA (%) is ranked higher than
96% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. PFE: 12.78 )
PFE' s 10-Year ROA (%) Range
Min: 3.35   Max: 25.31
Current: 12.78

3.35
25.31
ROC (Joel Greenblatt) (%) 83.18
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. PFE: 83.18 )
PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.53   Max: 88.78
Current: 83.18

19.53
88.78
Revenue Growth (%) -2.50
PFE's Revenue Growth (%) is ranked higher than
56% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PFE: -2.50 )
PFE' s 10-Year Revenue Growth (%) Range
Min: -2.5   Max: 19.1
Current: -2.5

-2.5
19.1
EBITDA Growth (%) 11.80
PFE's EBITDA Growth (%) is ranked higher than
77% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. PFE: 11.80 )
PFE' s 10-Year EBITDA Growth (%) Range
Min: -4.7   Max: 35.5
Current: 11.8

-4.7
35.5
EPS Growth (%) 17.00
PFE's EPS Growth (%) is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. PFE: 17.00 )
PFE' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 90.5
Current: 17

-26.8
90.5
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PFE Guru Trades in Q3 2013

Louis Moore Bacon 17,687 sh (New)
Ray Dalio 54,608 sh (New)
Paul Tudor Jones 950,000 sh (+380.53%)
Joel Greenblatt 65,050 sh (+259.55%)
Jean-Marie Eveillard 8,276,410 sh (+174.32%)
John Buckingham 60,187 sh (+73.94%)
Mario Gabelli 1,202,843 sh (+14.31%)
Diamond Hill Capital 7,992,003 sh (+0.51%)
Manning & Napier Advisors, Inc 1,119,010 sh (+0.15%)
David Dreman 71,195 sh (+0.14%)
James Barrow 60,897,666 sh (+0.11%)
Jeff Auxier 166,874 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 10,422 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Robert Bruce 432,000 sh (unchged)
Michael Price 347,100 sh (unchged)
Donald Yacktman 41,700 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Ken Fisher 30,714,170 sh (-0.08%)
Murray Stahl 58,665 sh (-0.37%)
John Keeley 106,620 sh (-0.51%)
RS Investment Management 2,105,755 sh (-0.96%)
Dodge & Cox 67,406,435 sh (-1.15%)
Irving Kahn 2,508,002 sh (-1.32%)
Bill Frels 2,584,820 sh (-1.34%)
HOTCHKIS & WILEY 202,100 sh (-1.41%)
Charles Brandes 6,360,407 sh (-1.72%)
Ronald Muhlenkamp 34,944 sh (-3.9%)
Pioneer Investments 9,473,843 sh (-5.05%)
Vanguard Health Care Fund 21,393,422 sh (-10.74%)
NWQ Managers 11,116,160 sh (-12.7%)
Jeremy Grantham 47,726,111 sh (-17.75%)
Steven Cohen 113,826 sh (-93.25%)
» More
Q4 2013

PFE Guru Trades in Q4 2013

Jim Simons 7,499,841 sh (New)
Joel Greenblatt 222,280 sh (+241.71%)
Ray Dalio 110,408 sh (+102.18%)
Ronald Muhlenkamp 45,129 sh (+29.15%)
Jean-Marie Eveillard 10,186,005 sh (+23.07%)
Ruane Cunniff 11,022 sh (+5.76%)
Murray Stahl 61,605 sh (+5.01%)
John Buckingham 63,034 sh (+4.73%)
Robert Bruce 452,000 sh (+4.63%)
Diamond Hill Capital 8,339,063 sh (+4.34%)
James Barrow 61,461,287 sh (+0.93%)
Brian Rogers 12,287,115 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Michael Price 347,100 sh (unchged)
Louis Moore Bacon Sold Out
Donald Yacktman Sold Out
Ken Fisher 30,626,382 sh (-0.29%)
Bill Frels 2,570,105 sh (-0.57%)
RS Investment Management 2,072,255 sh (-1.59%)
Mario Gabelli 1,183,743 sh (-1.59%)
John Keeley 104,466 sh (-2.02%)
Dodge & Cox 65,289,814 sh (-3.14%)
HOTCHKIS & WILEY 194,900 sh (-3.56%)
NWQ Managers 10,684,522 sh (-3.88%)
Jeff Auxier 159,324 sh (-4.52%)
Pioneer Investments 9,027,655 sh (-4.71%)
Manning & Napier Advisors, Inc 1,027,334 sh (-8.19%)
Steven Cohen 103,596 sh (-8.99%)
Charles Brandes 5,767,402 sh (-9.32%)
Irving Kahn 1,899,759 sh (-24.25%)
Vanguard Health Care Fund 12,153,122 sh (-43.19%)
Jeremy Grantham 26,803,828 sh (-43.84%)
David Dreman 10,163 sh (-85.73%)
Paul Tudor Jones 46,247 sh (-95.13%)
» More
Q1 2014

PFE Guru Trades in Q1 2014

John Hussman 17,000 sh (New)
Caxton Associates 100,000 sh (New)
Louis Moore Bacon 200,452 sh (New)
Paul Tudor Jones 875,000 sh (+1792.01%)
Joel Greenblatt 1,014,808 sh (+356.54%)
Steven Cohen 295,765 sh (+185.5%)
David Dreman 11,851 sh (+16.61%)
Irving Kahn 2,112,819 sh (+11.22%)
Diamond Hill Capital 8,790,937 sh (+5.42%)
John Buckingham 65,971 sh (+4.66%)
Murray Stahl 62,855 sh (+2.03%)
Ray Dalio 112,108 sh (+1.54%)
RS Investment Management 2,080,155 sh (+0.38%)
Robert Bruce 452,000 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 11,022 sh (unchged)
Michael Price 347,100 sh (unchged)
Bill Frels 2,561,304 sh (-0.34%)
HOTCHKIS & WILEY 194,200 sh (-0.36%)
Charles Brandes 5,743,711 sh (-0.41%)
Ken Fisher 30,242,537 sh (-1.25%)
Mario Gabelli 1,165,574 sh (-1.53%)
Dodge & Cox 64,121,017 sh (-1.79%)
James Barrow 59,895,571 sh (-2.55%)
Pioneer Investments 8,653,390 sh (-4.15%)
John Keeley 95,893 sh (-8.21%)
Jeff Auxier 145,881 sh (-8.44%)
Ronald Muhlenkamp 41,169 sh (-8.77%)
Manning & Napier Advisors, Inc 899,181 sh (-12.47%)
NWQ Managers 9,231,207 sh (-13.6%)
Jean-Marie Eveillard 7,866,473 sh (-22.77%)
Vanguard Health Care Fund 7,276,622 sh (-40.13%)
Jeremy Grantham 6,741,800 sh (-74.85%)
Jim Simons 454,241 sh (-93.94%)
» More
Q2 2014

PFE Guru Trades in Q2 2014

Vanguard Health Care Fund 14,934,022 sh (+105.23%)
Ken Fisher 31,482,489 sh (+4.1%)
Brian Rogers 12,287,115 sh (unchged)
Manning & Napier Advisors, Inc 882,317 sh (-1.88%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 105.23%0.62%$29.02 - $32.4 $ 28.7-4%14934022
Vanguard Health Care Fund 2014-03-31 Reduce -40.13%0.48%$29.66 - $32.75 $ 28.7-8%7276622
Joel Greenblatt 2014-03-31 Add 356.54%0.38%$29.66 - $32.75 $ 28.7-9%1014808
Jean-Marie Eveillard 2014-03-31 Reduce -22.77%0.19%$29.66 - $32.75 $ 28.7-9%7866473
John Hussman 2014-03-31 New Buy0.04%$29.66 - $32.75 $ 28.7-8%17000
Vanguard Health Care Fund 2013-12-31 Reduce -43.19%0.91%$28.24 - $32.2 $ 28.7-6%12153122
Charles Brandes 2013-12-31 Reduce -9.32%0.22%$28.24 - $32.2 $ 28.7-6%5767402
Jean-Marie Eveillard 2013-12-31 Add 23.07%0.16%$28.24 - $32.2 $ 28.7-6%10186005
David Dreman 2013-12-31 Reduce -85.73%0.15%$28.24 - $32.2 $ 28.7-6%10163
Joel Greenblatt 2013-12-31 Add 241.71%0.11%$28.24 - $32.2 $ 28.7-6%222280
Ronald Muhlenkamp 2013-12-31 Add 29.15%0.05%$28.24 - $32.2 $ 28.7-6%45129
Donald Yacktman 2013-12-31 Sold Out 0.01%$28.24 - $32.2 $ 28.7-6%0
Ray Dalio 2013-12-31 Add 102.18%0.01%$28.24 - $32.2 $ 28.7-6%110408
Jean-Marie Eveillard 2013-09-30 Add 174.32%0.44%$27.65 - $29.67 $ 28.70%8276410
Vanguard Health Care Fund 2013-09-30 Reduce -10.74%0.27%$27.65 - $29.67 $ 28.70%21393422
Joel Greenblatt 2013-09-30 Add 259.55%0.04%$27.65 - $29.67 $ 28.70%65050
Ray Dalio 2013-09-30 New Buy0.01%$27.65 - $29.67 $ 28.70%54608
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc - Jul 25, 2014

Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc
Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed. Read more...
Guru Favorites Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to:Have a dividend of greater than 3%. Have a strong history of stable and increasing dividends. Maintain Guru ownership. Have a market cap of greater than $10 billion.The following four companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.A comparison of the companies’ historical dividend growth:AT&T (T)On June 27, AT&T declared a dividend of $0.46 per share, representing 5.20% dividend yield for the company. This dividend is payable on August 1 to shareholders of the record at the close of business on July 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 4.40%- 5-year: 2.30%- 3-year: 2.30%AT&T is a communications holding company. Its subsidiaries and affiliates are the providers of AT&T services in the U.S. and internationally. The company holds a portfolio of the nation’s fastest and most reliable 4G LTE network, wireless internet, Wi-Fi and voice and cloud-based services.AT&T’s historical revenue and net income:The analysis on AT&T reports that the company’s price is near a 5-year high, it has issued $12.6 billion in debt over the past three years and its operating income has been in loss over the past three years. On the other hand the analysis also notes that the Piotroski F-Score is high, its dividend yield is near a 2-year high and its P/E, P/S and P/B ratios are all trading at around historical lows.The Peter Lynch Chart suggests that the company is currently undervalued:AT&T has a market cap of $184.3 billion. Its shares are currently trading at around $35.51 with a P/E ratio of 10.40 and a P/S ratio of 1.50. The company had an annual average earnings growth of 4.10% over the past ten years.Lockheed Martin (LMT)On June 26, Lockheed Martin declared a dividend of $1.33 per share, representing 3.20% dividend yield for the company. This dividend is payable on Sept. 26 to shareholders of the record at the close of business on Sept. 2, 2014.

The company’s historical dividend growth is as follows:- 10-year: 20.90%- 5-year: 20.70%- 3-year: 21.90%Lockheed Martin is a security company that is principally engaged in the research, design, development, manufacture, integration, and sustainment of advanced technology systems and products. It also provides a range of management, engineering, technical, scientific, logistic, and information services.Lockheed Martin’s historical revenue and earnings growth:The analysis on Lockheed Martin reports that the company’s revenue has been in decline over the past month, its dividend yield is near a 3-year low and its price is near a 10-year high.The Peter Lynch Chart suggests that the company is currently overvalued:Lockheed Martin has a market cap of $51.02 billion. Its shares are currently trading at around $160.75 with a P/E ratio of 16.50, a P/S ratio of 1.20 and a P/B ratio of 10.50. The company had an annual average earnings growth of 9.90% over the past ten years.GuruFocus rated Lockheed Martin the business predictability rank of 3-star.Pfizer (PFE)On June 26, Pfizer declared a dividend of $0.260 per share, representing 3.40% dividend yield for the company. This dividend is payable on Sept. 3 to shareholders of the record at the close of business on Aug. 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 1.20%- 5-year: 5.80%- 3-year: 10.10%Pfizer is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include areas of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.Pfizer’s historical revenue and net income:The analysis on Pfizer reports that the company’s revenue has been in decline over the past year, the dividend yield is near a 5-year low, the price is near a 5-year high and its operating margin is expanding.The Peter Lynch Chart suggests that the company is currently undervalued:Pfizer has a market cap of $192.19 billion. Its shares are currently trading at around $30.13 with a P/E ratio of 9.60, a P/S ratio of 4.00 and a P/B ratio of 2.70. The company had an annual average earnings growth of 3.40% over the past ten years.GuruFocus rated Pfizer the business predictability rank of 3-star.Freeport-McMoRan Copper & Gold (FCX)On June 25, Freeport-McMoRan declared a dividend of $0.313 per share, representing 3.40% dividend yield for the company. This dividend is payable on Aug. 1 to shareholders of the record at the close of business on July 15, 2014.

The company’s historical dividend growth is as follows:- 10-year: 0.00%- 5-year: 0.00%- 3-year: 40.60%Freeport-McMoRan is a U.S.-based natural resource company with an industry leading global portfolio of mineral assets, significant oil and gas resources and a growing production profile.Freeport-McMoRan’s historical revenue and net income:The analysis on Freeport-McMoRan reports that the company’s asset growth is faster than its revenue growth and its P/S ratio is close to a 2-year low.The Peter Lynch Chart shows that the company is currently undervalued:Freeport-McMoRan Copper & Gold has a market cap of $38.43 billion. Its shares are currently trading at around $37.00 with a P/E ratio of 15.10, a P/S ratio of 1.80 and a P/B ratio of 1.50. The dividend yield for the company is currently sitting at 3.40%.To view a complete list of high yielding dividend stocks found among the gurus’ portfolios, click here.

Try a free 7-day premium membership. Read more...
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014?
Pfizer (PFE) will release its first quarter 2014 earnings report before the opening bell on Monday, May 5, 2014. Since the company has posted higher than expected earnings over the past three quarters, analysts and investors are looking for the pharmaceutical giant to beat the Street’s estimates once again. Read more...
Pfizer and Lockheed Martin Top Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
AT&T and Pfizer Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to:
Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...
Vanguard Health Care Fund Selling Update
The updated portfolio of the Vanguard Health Care Fund lists 92 stocks, four of them new, a total value at $29.45 billion, and a quarter-over-quarter turnover of 4%. The portfolio is weighted with two sectors: health care at 91.5% and consumer defensive at 2.9%. Vanguard Health Care Fund has averaged a return of 24.96% over 12 months and 9.5% over 10 years, according to the GuruFocus Score Board of Gurus. Read more...
GuruFocus' Weekly Dividend Growers Pt. 2
During the past week, GuruFocus recognized 10 companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Passion and Compassion - Paul Tudor Jones, Sells in Review
Passion and compassion are the two engines that drive "venture philanthropist" Paul Tudor Jones II, founder, chairman and CEO of The Tudor Group. Passion fuels his vocation as a hedge fund trader extraordinaire. As of this month, Jones has amassed a personal fortune of around $3.7 billion, according to Forbes. Compassion clearly energizes his avocation, helping homeless children and the poor. Paul Tudor Jones is the founder of Robin Hood, a charitable organization formed in 1988 to target poverty in New York City. Its board of directors is peopled with a number of Guru billionaire investors. In his 2011 speech at the Robin Hood Heroes Breakfast, Jones outlined the various kinds of poverty, the worst being a poverty of opportunity Americans are facing. Last year, Robin Hood invested $132 million in 210 poverty-fighting programs. Read more...
Pennant Capital Sells in Review
The updated portfolio of value investor Alan Fournier, fund manager of Pennant Capital Management, lists 46 stocks, eight of them new. His portfolio has a total value of $5.57 billion, with a quarter-over-quarter turnover of 15%. Pennant Capital currently invests in technology with a sector weighting of 26.3%, consumer cyclical at 25.3%, healthcare at 8.9% and financial services at 6.8%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 9.50
PFE's P/E(ttm) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. PFE: 9.50 )
PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 200.11
Current: 9.5

7.67
200.11
P/B 2.40
PFE's P/B is ranked higher than
75% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. PFE: 2.40 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.55
Current: 2.4

1.32
4.55
P/S 3.90
PFE's P/S is ranked higher than
66% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. PFE: 3.90 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 6.36
Current: 3.9

1.72
6.36
PFCF 11.70
PFE's PFCF is ranked higher than
96% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 11.70 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 35.16
Current: 11.7

5.02
35.16
EV-to-EBIT 13.67
PFE's EV-to-EBIT is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. PFE: 13.67 )
PFE' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 69.7
Current: 13.67

7.9
69.7
PEG 2.20
PFE's PEG is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 367.50 vs. PFE: 2.20 )
PFE' s 10-Year PEG Range
Min: 1.14   Max: 584
Current: 2.2

1.14
584
Shiller P/E 17.10
PFE's Shiller P/E is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 17.10 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 39.64
Current: 17.1

8.49
39.64
Current Ratio 2.33
PFE's Current Ratio is ranked higher than
70% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. PFE: 2.33 )
PFE' s 10-Year Current Ratio Range
Min: 0.98   Max: 3.18
Current: 2.33

0.98
3.18
Quick Ratio 2.09
PFE's Quick Ratio is ranked higher than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. PFE: 2.09 )
PFE' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.86
Current: 2.09

0.74
2.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.50
PFE's Dividend Yield is ranked higher than
89% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. PFE: 3.50 )
PFE' s 10-Year Dividend Yield Range
Min: 1.54   Max: 10.4
Current: 3.5

1.54
10.4
Dividend Payout 0.65
PFE's Dividend Payout is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 0.65 )
PFE' s 10-Year Dividend Payout Range
Min: 0.12   Max: 8.21
Current: 0.65

0.12
8.21
Dividend growth (3y) 10.10
PFE's Dividend growth (3y) is ranked higher than
84% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. PFE: 10.10 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 10.1

-14.7
22.6
Yield on cost (5-Year) 4.64
PFE's Yield on cost (5-Year) is ranked higher than
90% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. PFE: 4.64 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.04   Max: 13.79
Current: 4.64

2.04
13.79
Share Buyback Rate 5.10
PFE's Share Buyback Rate is ranked higher than
92% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.70 vs. PFE: 5.10 )
PFE' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -19
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
PFE's Price/DCF (Projected) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 0.90 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 8.57
Current: 0.9

0.53
8.57
Price/Median PS Value 1.10
PFE's Price/Median PS Value is ranked higher than
72% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. PFE: 1.10 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.63
Current: 1.1

0.51
3.63
Price/Peter Lynch Fair Value 2.00
PFE's Price/Peter Lynch Fair Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 2.00 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.13   Max: 36.51
Current: 2

1.13
36.51
Earnings Yield (Greenblatt) 7.30
PFE's Earnings Yield (Greenblatt) is ranked higher than
81% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. PFE: 7.30 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 12.6
Current: 7.3

1.4
12.6
Forward Rate of Return (Yacktman) 14.42
PFE's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. PFE: 14.42 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.6   Max: 20.7
Current: 14.42

7.6
20.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany
Pfizer was founded in 1849 and is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include ares of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary care, Specialty Care and Oncology are responsible for life-cycle management of in-line products and new proof of concept therapies. Pfizer's Board of Directors is responsible for the oversight of management, including the overall strategic direction of the company and for the company's policies on governance, executive compensation, transparency and compliance.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
Diamond Hill Capital Comments on Pfizer Inc Jul 25 2014 
Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
Pfizer: A Fairly Valued Stock Jul 23 2014 
Although This Hedge Fund Changed Stocks in Three of Them Bet More Jul 21 2014 
Guru Favorites Top GuruFocus Dividend Growers of the Weeks Jul 01 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 

More From Our Partners
Is the Q2 Earnings Improvement Sustainable? - Earnings Preview Jul 25 2014 - ZACKS

More From Other Websites
Europe closes at 3-week low; infation data, Portugal weighs Jul 31 2014
[video] Catalent CEO: Leading advanced drug delivery Jul 31 2014
AstraZeneca steps up push into cancer immunotherapy Jul 31 2014
AstraZeneca steps up push into cancer immunotherapy Jul 31 2014
AstraZeneca raises forecasts after seeing off Pfizer Jul 31 2014
AstraZeneca raises forecasts after seeing off Pfizer Jul 31 2014
AstraZeneca raises forecasts after seeing off Pfizer Jul 31 2014
AstraZeneca: 'Execution risk' to Pfizer deal Jul 31 2014
BG, Shell boost Britain's FTSE after profits rise Jul 31 2014
[$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review Jul 31 2014
Why There's Far More To Pfizer Than Viagra Jul 30 2014
Top defensive picks in offensive sectors Jul 30 2014
Pfizer buying two Baxter vaccines for $635M Jul 30 2014
Pfizer buying two Baxter vaccines for $635M Jul 30 2014
10:34 am Pfizer: InnoPharma announces launch of Olanzapine for injection, 10mg/vial in Canada Jul 30 2014
InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada Jul 30 2014
Why Pfizer (PFE) Stock Is Down Today Jul 30 2014
Pfizer to buy Baxter's vaccines unit for $635 mln Jul 30 2014
Pfizer to buy Baxter’s vaccines for $635 million Jul 30 2014
[$$] Pfizer To Buy Baxter's Vaccines Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

SEENSCO
ReplySEENSCO - 1 month ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide